WEST LAFAYETTE, Ind., Nov. 18, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT - News), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:^NBI - News) as part of NASDAQ’s semi-annual re-ranking. Endocyte’s inclusion in the index will become effective prior to market open on Monday, Nov. 21, 2011. The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is the basis for the iShares Nasdaq Biotechnology IndexSM Fund (Nasdaq:IBB - News), which seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the NASDAQ Biotechnology Index. In addition, options based on the NASDAQ Biotechnology Index and the iShares Nasdaq Biotechnology Index Fund trade on various exchanges.
